A Chinese inactivated COVID-19 vaccine candidate has been proved safe and tolerable and can induce a quick immune response, according to the findings from early and mid-stage clinical trials published in the journal The Lancet Infectious Diseases.

A COVID-19 vaccine candidate developed by the Institute of Microbiology under the Chinese Academy of Sciences has shown to be safe in early-stage trials.

U.S. pharmaceutical company Johnson & Johnson said Monday it had paused its COVID-19 vaccine trial because one of its participants had become sick.

An inactivated Covid-19 vaccine candidate developed by China has shown promising trial result as it is safe and generates an immune response, according to data from clinical trials published in The Journal of the American Medical Association this week.